Company Encyclopedia
View More
name
Nuvation Bio
NUVB.US
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
4.400 T
NUVB.USMarket value -Rank by Market Cap -/-

Financial Score

19/11/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking62/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-52.49%E
    • Profit Margin-813.07%E
    • Gross Margin74.47%A
  • Growth ScoreA
    • Revenue YoY1137.19%A
    • Net Profit YoY59.14%B
    • Total Assets YoY5.25%B
    • Net Assets YoY-35.18%E
  • Cash ScoreB
    • Cash Flow Margin-12.30%D
    • OCF YoY1137.19%A
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreC
    • Gearing Ratio45.83%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nuvation shares are trading higher after B. Riley initiated coverage on the stock with a Buy rating and announced a $12 price target.

    benzinga_article·
    US
    NUVB
    +41.56%
    benzinga_article·
    US
    NUVB
    +41.56%

    Positive Outlook on Nuvation Bio’s Safusidenib Driven by Promising Clinical Data and Strategic Focus

    JonesTrading analyst Soumit Roy maintains a Buy rating on Nuvation Bio (NUVB) stock, driven by promising clinical data and strategic focus on safusidenib, an IDH1 inhibitor. Recent Phase 2 trial data from Daiichi Sankyo shows a 44% response rate and 88% progression-free survival at 24 months. Nuvation Bio's alignment with the FDA and focus on unmet medical needs, along with strong financials, support this positive outlook. H.C. Wainwright also reiterates a Buy rating with a $10 price target.

    Tip Ranks·
    US
    NUVB
    +41.56%
    Tip Ranks·
    US
    NUVB
    +41.56%

    Nuvation Bio Reports Positive Phase 2 Study Results

    Nuvation Bio announced positive Phase 2 results for safusidenib in Japanese patients with IDH1-mutant gliomas, showing a 44.4% response rate and potential to delay disease progression. Despite safety reporting noncompliance, the company plans a global Phase 3 trial for regulatory approval. Analysts rate NUVB stock as Buy with an $8.00 target, but Spark's AI Analyst views it as Neutral due to weak financials and speculative nature.

    Tip Ranks·
    US
    NUVB
    +41.56%
    Tip Ranks·
    US
    NUVB
    +41.56%

    Officer Liu Files To Sell 15,000 Of Nuvation Bio Inc [NUVB]

    Officer Liu Dongfang of Nuvation Bio Inc filed a Form 144 with the SEC to sell 15,000 restricted shares on November 17, 2025. The sale will be brokered by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing.

    Reuters·
    US
    NUVB
    +41.56%
    Reuters·
    US
    NUVB
    +41.56%

    Nuvation Bio (NYSE:NUVB) Sees Strong Trading Volume on Earnings Beat

    Nuvation Bio Inc. (NYSE:NUVB) experienced a surge in trading volume, with 6.78 million shares traded after reporting better-than-expected quarterly earnings. The company posted an EPS of ($0.16), surpassing estimates, and revenue of $13.12 million, exceeding expectations. Analysts have mixed ratings, with one Strong Buy, seven Buy, and one Sell. The stock is currently down 12% and has a market cap of $1.56 billion. Nuvation Bio focuses on developing oncology therapeutics, including its lead candidate NUV-868.

    Market Beat·
    US
    NUVB
    +41.56%
    Market Beat·
    US
    NUVB
    +41.56%